Research Group
Breast and Gynecologic Cancer
Sponsor
National Cancer Institute (NCI)
Status
Recruiting
NCT ID
NCT06184750
This phase II trial evaluates response-guided low-dose tamoxifen for reducing breast density in women who are at higher than average risk for breast cancer. Increasing breast density is a well established risk factor for breast cancer. Tamoxifen is a selective estrogen receptor modulator. It works by blocking the effects of the hormone estrogen in the breast. Tamoxifen has been shown to reduce breast density, even at reduced dosages, and is approved for the prevention of breast cancer.
Intervention
Biopsy Procedure, Biospecimen Collection, Mammography, Questionnaire Administration, Tamoxifen
Condition
Breast Atypical Ductal Hyperplasia, Breast Atypical Lobular Hyperplasia, Breast Carcinoma, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ, Estrogen Receptor-Positive Breast Carcinoma
Investigators
Seema A. Khan, Kevin S. Hughes, Parijatham (Priya) S. Thomas, Adetunji T. Toriola, Kent F. Hoskins, Melissa L. Pilewskie, Carol J. Fabian, Amanda L. Amin, Judy E. Garber, Elizabeth A. Mittendorf, Sima Ehsani Chimeh
CT Research Area
Prevention